Navigation Links
Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010
Date:10/27/2010

BOSTON, Oct. 27 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company generated revenues during the three months ended September 30, 2010 in the amount of $134,426 versus $99,710 for the three months ended September 30, 2009.  This was an increase of 34.8% for the three months during 2010 as compared to 2009.

Despite a down global economy, Solos has been able to increase its sales transactions due to consistent product orders from the Company's current customer base. Over the past twelve months, Solos has placed an emphasis on promoting and marketing its MammoView® product line to hospitals and cancer centers. Revenue for the third quarter was driven by sales from the MammoView® line as well as strong sales from its standard product line with increased orders for the Company's Vascular Clamp System.

"We completed another strong quarter of sales in 2010," stated Bob Segersten, President of Solos Endoscopy, Inc. "Year-to-date, we have delivered double-digit revenue growth in what continues to be a challenging economic environment."

The Company expects to post its full unaudited financial results for the three months ended September 30, 2010 on the Pink Sheets OTC Markets website within in the next forty-five days.

Throughout the remainder of 2010, the Company will continue its new product development for the MammoView® product line. In addition, Solos plans to achieve market expansion through its efforts to meet the requirements of the ISO 13485 standard and ultimately obtain the CE Mark and the permission to sell medical devices in the European Union and Canada.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy, Inc. Announces Results of 2010 Annual Shareholder Meeting
2. Solos Endoscopy, Inc. to Hold Annual Shareholder Meeting September 28, 2010
3. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
4. Solos Endoscopy, Inc. Increases Revenues by 10 Percent for First Quarter 2010 as Compared to First Quarter 2009
5. Solos Endoscopy, Inc. Appoints Experienced CFO To Financial Leadership Amidst Growth
6. Solos Endoscopy, Inc. Granted U.S. Trademark for MammoView(R)
7. Solos Endoscopy, Inc. Set To Develop European Union Conforming CE Mark Technical File
8. Solos Endoscopy, Inc. Set To Develop New Polymer Dilator For MammoView(TM) System
9. Solos Endoscopy, Inc. Retains Expert Resource to Meet Requirements for ISO 13485 Quality Management System Initiative
10. Solos Endoscopy, Inc.s Breast Endoscopy System Featured in February Issue of General Surgery News
11. Solos Endoscopy, Inc. Set to Increase Business Through Sales and Product Development in 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... A recent research report published by Grand ... is expected to reach a value of $55.8 billion by 2025. ... 28 states have legalized marijuana for medical uses. In 2016, states ... , North Dakota , Ohio ... the drug in medical applications such as chemotherapies and pain management. ...
(Date:2/27/2017)... 27, 2017 Period October – December 2016 ... result amounted to SEK -16.4 (-6.4) million Result after tax ... before and after dilution Cash flow from operating activities amounted ... ... (0.4) million Operating result amounted to SEK -39.5 (-29.5) million ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Wireless Health Market is ... next decade to reach approximately $330.5 billion by 2025. ... the given segments on global as well as regional levels presented ...
Breaking Medicine Technology:
(Date:2/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... use disorder, but concern for women who become dependent on opioid painkillers has fallen ... among female patients, compared to a 237% increase in fatal overdoses in male populations.(1) ...
(Date:2/27/2017)... ... ... Orange County dentist, Dr. A. Rassouli, comments on the new ... bacteria in plaque infect the gums and other tissues supporting the teeth. Treatment typically ... SRP, and can include surgical therapies if the condition has led to significant damage. ...
(Date:2/27/2017)... ... ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from the International Lyme and Associated ... Disease Control ( CDC ) and Infectious Diseases Society of America (IDSA) dismiss any ... into a single volume a compelling argument that the disease does exist in his ...
(Date:2/27/2017)... Francisco, CA (PRWEB) , ... February 27, 2017 ... ... center for hair transplantation therapy, is proud to announce a new informational post ... hair therapy procedures. Follicular Unit Extraction (FUE) hair transplant and Follicular Unit Transplantation ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of ... concern over nerve agents and the deadly use of chemical weapons. Many questions exist ... how even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan ...
Breaking Medicine News(10 mins):